180 Wealth Advisors LLC Raises Holdings in Veru Inc. (NASDAQ:VERU)

180 Wealth Advisors LLC increased its position in shares of Veru Inc. (NASDAQ:VERU) by 41.0% in the 4th quarter, Holdings Channel reports. The firm owned 293,350 shares of the company’s stock after purchasing an additional 85,350 shares during the period. 180 Wealth Advisors LLC’s holdings in Veru were worth $191,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in VERU. Bank of New York Mellon Corp increased its position in shares of Veru by 1,718.2% during the second quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock worth $373,000 after purchasing an additional 419,374 shares in the last quarter. Rhumbline Advisers boosted its stake in Veru by 3,994.8% during the second quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock worth $96,000 after buying an additional 110,857 shares during the last quarter. Choreo LLC boosted its stake in Veru by 261.3% during the second quarter. Choreo LLC now owns 332,050 shares of the company’s stock worth $292,000 after buying an additional 240,134 shares during the last quarter. Blair William & Co. IL boosted its stake in Veru by 6.1% during the second quarter. Blair William & Co. IL now owns 350,000 shares of the company’s stock worth $294,000 after buying an additional 20,000 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in Veru during the second quarter worth $161,000. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

Veru Stock Down 0.4 %

Shares of Veru stock opened at $0.74 on Thursday. Veru Inc. has a 52 week low of $0.36 and a 52 week high of $1.92. The business’s fifty day simple moving average is $0.69 and its 200-day simple moving average is $0.80. The firm has a market cap of $108.40 million, a PE ratio of -1.54 and a beta of -0.53.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Monday, December 16th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. As a group, equities analysts expect that Veru Inc. will post -0.3 earnings per share for the current year.

Analysts Set New Price Targets

VERU has been the topic of a number of recent research reports. Oppenheimer reissued an “outperform” rating and set a $5.00 price objective on shares of Veru in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of Veru in a research note on Thursday, January 2nd.

Veru Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.